

PRECEPTORSHIP

New developments in specific risks groups of ALL

A highly interactive postgraduate educational program

May 19 & 20, 2025 Utrecht, The Netherlands

Do you want to improve the outcome of your patients? Join the interactive Preceptorship meeting and interact with leading international experts. The number of participants is limited!

For more information and the program turn this page or scan the OR-code.



^{*}Application has been made to the EACCME for CME accreditation

Program

Session I: New developments for specific patient populations

- Infant ALL
- Adolescent and young adult ALL
- T-ALL
- Treatment of children with CNS disease

Session II: Treatment strategies for specific molecular and immunological subgroups

- Molecular genetic diagnostics, MRD and risk stratification
- BCR-ABL/BCR-ABL-like
- Monoclonal therapy in ALL
- Allo-SCT versus CAR T-cell therapy

Session III: New approaches to reduce toxicity

- Asparaginase + including TDM
- Direct and late toxicity
- How to reduce therapy?
- Towards individualized relapse treatment

Set-up	Each session will last 4 hours hosted by faculty members who will rotate between the 4 subgroups. Because of this we create a unique and intensive interaction between the participants and the experts that is only available for onsite participation.
Selection criteria	High-potentials actively involved or interested in New developments in specific risk groups of ALL (pediatric oncologists and hematologists (whether or not in training), and other experts in the field).
Fee	€ 350 early bird (till December 1), including social program € 450 full fare (from December 1), including social program
Registration	until April 21, 2025
Local Organizing Committee	Gertjan Kaspers, Rob Pieters, Janine Stutterheim, Lenneke Schrier
Mail contact	Gertjan Kaspers – Director Academy & Outreach Lenneke Schrier – Pediatric oncologist events@prinsesmaximacentrum.nl